TheraCal Materials Versus MTA in Full Pulpotomy

The goal of this randomized clinical trial is to compare the clinical performance of three pulp capping materials used in full pulpotomy procedures in mature mandibular molars with symptomatic irreversible pulpitis. The main questions it aims to answer are: * Does full pulpotomy using mineral trioxide aggregate (MTA) provide favorable postoperative pain control and 12-month clinical success? * Does full pulpotomy using TheraCal LC provide comparable postoperative pain control and 12-month clinical success to MTA? * Does full pulpotomy using TheraCal PT provide comparable postoperative pain control and 12-month clinical success to MTA? Participants will undergo full pulpotomy treatment in mandibular first or second molars diagnosed with symptomatic irreversible pulpitis. After removal of the coronal pulp tissue and achievement of hemostasis, teeth will be randomly assigned to one of three treatment groups. In the MTA group, the exposed radicular pulp tissue will be covered with mineral trioxide aggregate. In the TheraCal LC group, the exposed radicular pulp tissue will be covered with light-cured resin-modified calcium silicate material. In the TheraCal PT group, the exposed radicular pulp tissue will be covered with dual-cured resin-modified calcium silicate material. Postoperative pain intensity, analgesic intake, and 12-month clinical outcomes will be compared among the three groups.

NCT Number	NCT07660549
Lead Sponsor	Cukurova University
Conditions	Pulpitis - Irreversible
Enrollment	72 participants
Start Date	2024-12-16
Primary Completion	2025-06-18 (estimated)
Study Completion	2026-04-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-25